企業ニュース

  • すべて
  • Corporate News
  • Events & Exhibitions

FarmaMondo announces the establishment of FarmaMondo JAPAC hub, in Singapore

The FarmaMondo Group announces the establishment of FarmaMondo Pte, a fully owned subsidiary in Singapore. FarmaMondo Pte Singapore will further serve the Group’s development strategy

FarmaMondo announces the establishment of FarmaMondo Iberia, in Portugal

February 2021 FarmaMondo SA announces the establishment of FarmaMondo Iberia, in Portugal, a fully owned subsidiary of FarmaMondo SA. The Iberian Subsidiary will further enhance

Sarepta Therapeutics and FarmaMondo announce an agreement to exclusively manage access of eteplirsen and golodirsen in Russia

December 2020 – FarmaMondo SA announced an exclusive distribution of eteplirsen and golodirsen for certain patients with Duchenne muscular dystrophy (DMD) in Russia. FarmaMondo SA,

Dompe’ farmaceutici and the FarmaMondo Group: exclusive agreement to distribute oxervate™ in Russia and other CIS countries

November 2020 – Dompé farmaceutici Spa and FarmaMondo entered into an exclusive Managed Access Program distribution agreement appointing the FarmaMondo Group as the exclusive partner

FarmaMondo new website is now LIVE!

FarmaMondo is pleased to announce the launch of its brand new website! After months of hard work and dedication, we are delighted to officially announce

Zion Medical appoints the FarmaMondo Group to support global named patient access to its novel therapy Gammora™

FarmaMondo and Zion Medical, an Israel startup pharma developer, signed today an agreement to establish a MAP for their novel drug Gammora. The product is

FarmaMondo to exclusively manage access to Metreleptin (Myalept®) by Amryt Pharma for patients with lipodystrophy in CIS (excluding Russia)

Amryt Pharma (www.amrytph

EUSA and FarmaMondo Group establishes an Emergency Managed Access Program to allow Healthcare Providers to access Siltuximab (Sylvant©) for off label treatment of acute patients of COVID-19

While the world fights th

FarmaMondo to exclusively Manage Access to Lomitapide (Lojuxta®) for the Swiss and CIS markets

Amryt Pharma (www.amrytph

FarmaMondo to exclusively manage access of Qarziba® (Dinutuximab Beta) by EUSA Pharma for patients with High Risk Neuroblastoma in LATAM and APAC regions

FarmaMondo SA, the world’

FarmaMondo to manage access to Carmustine Obvius for the Italian market

FarmaMondo has been appoi

FarmaMondo upgrades its presence in Mexico by establishing a local legal entity

FarmaMondo SA announces i

FarmaMondo Nordics receives GMP license from the Danish Medicines Agency

FarmaMondo Nordics Aps, a

FarmaMondo to manage access to Asparaginase (Spectrila® by Medac Pharma) for patients with acute lymphoblastic leukemia in Russia and CIS region

FarmaMondo SA, the world’

Merck’s Keytruda tops chemotherapy for non-small cell lung cancer treatment

Merck’s Keytruda (Pembrol

FDA extends use of Tagrisso to metastatic non-small-cell lung cancer

AstraZeneca’s Tagrisso ha

FarmaMondo To Attend Upcoming Pharmagora Paris – 2018

FarmaMondo Team is please

FarmaMondo appointed by Amomed Pharma to exclusively Manage Access for Argipressin (Empressin®) for Russia and CIS region

FarmaMondo SA, the world’

FarmaMondo establishes a new office in the Nordics

FarmaMondo: Bringing Responsible Access Global

Read the full interview,

FarmaMondo establishes presence in south EU markets to provide direct to hospital service around supply of unlicensed medicines

FarmaMondo SA announces i

FarmaMondo To Attend Upcoming Arab Health – 2018

FarmaMondo Team is please

CIS Medical Workshop around high risk Neuroblastoma management

FarmaMondo has recently h

FarmaMondo establishes presence in Mexico to provide direct to hospital service around supply of unlicensed medicines

FarmaMondo SA announces i

FarmaMondo to manage access to Dinutuximab beta EUSA for patients with Neuroblastoma

FarmaMondo to manage access to Qarziba® (Dinutuximab Beta) by EUSA Pharma) for patients with High Risk Neuroblastoma in Russia and CIS region

FarmaMondo SA, the world’

FARMAMONDO Exhibits at Expopharm 2017 in Düsseldorf

Following the successful

FarmaMondo to expand its operations in Russia and CIS

FarmaMondo is delighted t

FARMAMONDO Exhibits at Expopharm 2016 (Munich)

Following the successful

FarmaMondo at Early Access Programmes Conference in London

FarmaMondo is proud to sp

FarmaMondo appointed by Ideogen Pharma to Manage Access for Carmustine (Bicnu®) for Swiss market

FarmaMondo SA, the world’

Farmamondo and AOP signs exclusive partnership for Russia

Farmamondo and AOP Orphan

Farmamondo approves Normokineztine in Russia!

FarmaMondo approves Normo

FarmaMondo approves Ellanse in Taiwan

FarmaMondo announces the

FarmaMondo appointed by Rev Pharma to exclusively Manage Access for Curefini® outside the United States

FarmaMondo SA, the world’

FARMAMONDO honored as “Top trustworthy Swiss companies” by Dun & Bradstreet

FarmaMondo is proud to an

FarmaMondo re-position its Swiss retail unit to adapt to Group strategy

FarmaMondo completes a re

FarmaMondo establishes presence in Argentina to provide direct to hospital service around supply of unlicensed medicines

FarmaMondo SA announces i

FarmaMondo appointed by Orion Pharma to Manage Access for levosimendan IV (Simdax®) for Swiss market

FarmaMondo SA, the world’

FarmaMondo establishes Its Brazilian subsidiary

FarmaMondo announces the

FarmaMondo appointed by Adienne to Manage Access for Thiotepa (Tepadina®)

FarmaMondo SA, the world’

FarmaMondo establish presence in China

FarmaMondo SA announces i